.jpg)
%20Abstract%20Background%20112024%20SOURCE%20Amazon.jpg)
2 Absurdly Cheap Stocks to Buy and Hold for Years
Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.Stocks normally trade at discounts when there are concerns or question marks about the company's future performance. But in the case of Pfizer (NYSE: PFE) and Comcast (NASDAQ: CMCSA), the concerns look overblown. These are two great companies with stocks trading at absurdly low valuations. Here's why they're worth buying right now.Over the past five years, Pfizer's stock has gone from boom to bust. The pandemic sent the stock price soaring as demand for Pfizer's COVID-19 vaccine (Comirnaty) and prescription (Paxlovid) helped the business post record revenue and earnings. But with investors looking ahead and questioning where future growth will come from, especially as the company faces multiple patent cliffs, the stock proceeded to crash. Remarkably, the healthcare stock has now given back all of the gains it amassed during the pandemic and is trading lower than where it was five years ago, with its share price down 18% over that time frame.Continue reading
Buying stock in great companies when they are dealing with some short-term issue that creates stock price weakness can set investors up for big gains down the road. As long as the business is still in good shape, adding it to your portfolio when it's trading at a sizable discount can look like a brilliant move in the future.
Stocks normally trade at discounts when there are concerns or question marks about the company's future performance. But in the case of Pfizer (NYSE: PFE) and Comcast (NASDAQ: CMCSA), the concerns look overblown. These are two great companies with stocks trading at absurdly low valuations. Here's why they're worth buying right now.
Over the past five years, Pfizer's stock has gone from boom to bust. The pandemic sent the stock price soaring as demand for Pfizer's COVID-19 vaccine (Comirnaty) and prescription (Paxlovid) helped the business post record revenue and earnings. But with investors looking ahead and questioning where future growth will come from, especially as the company faces multiple patent cliffs, the stock proceeded to crash. Remarkably, the healthcare stock has now given back all of the gains it amassed during the pandemic and is trading lower than where it was five years ago, with its share price down 18% over that time frame.
